Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan (p
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
On 6ix: 6ix.com/news/ligand-partner-travere-therapeutics-announces-positive-topline-interim-results-from
Watch Ligand Pharmaceuticals' latest callLigand Pharmaceuticals (NASDAQ:LGND) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Ligand Pharmaceuticals (NASDAQ:LGND) Q2 2026 Earnings CallLigand Pharmaceuticals' next earnings callLigand Pharmaceuticals (NASDAQ:LGND) Q3 2026 Earnings Call · Oct 29, 2026 at 8:30 AM EDTRegister
Ligand Pharmaceuticals Incorporated on 6ix
Story so far
- Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
- Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Earlier from Ligand Pharmaceuticals
- Ligand Reports Second Quarter 2021 Financial Results
- Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
- Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
- Ligand to Report Second Quarter Financial Results on July 29, 2021
- Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
Later from Ligand Pharmaceuticals
- Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
- Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
- Ligand to Report Third Quarter Financial Results on November 9, 2021
- Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
- Ligand Reports Third Quarter 2021 Financial Results
Follow Ligand Pharmaceuticals into a list and get an email when it puts out news.
Follow Ligand Pharmaceuticals